“we look forward to putting our next candidate into the clinic in 2025 and sharing more about its profile later this year.”

In context

“for a second Nectin-4 ADC. We view this as an important target and having two compounds in the clinic provides more opportunities to improve outcomes for patients. We've also initiated a Phase 1 trial for our ADC targeting the folate receptor. This asset, which came from our acquisition of Mablink is the next-generation construct design -- efficacy at all fully receptor expression levels and with an improved therapeutic index relative to existing agents. We're also announcing that we've terminated the LOXO-783 program, which targeted PI3 kinase alpha. We evaluated the ongoing clinical data from the program and compared the molecule to next-generation candidates that we have progressed from our discovery efforts. We believe our next molecules have greater potential to benefit patients and we look forward to putting our next candidate into the clinic in 2025 and sharing more about its profile later this year. In immunology, we've now submitted mirikizumab for the treatment of moderately to severely active Crohn's disease in Japan. We've terminated development for our GITR agonist, antagonists due to insufficient efficacy. We also announced our acquisition of Morphic. And pending completion of the deal we plan to reflect the oral alpha-4-beta-7 integrin inhibitor, MORF-057, in Phase 2 for ulcerative colitis and Crohn's disease. Finally, in neuroscience, our anti-tau small molecule OGA inhibitor, recently concluded its Phase 2 study in early symptomatic Alzheimer's disease. OGA failed to meet the primary endpoint of decreasing the change of baseline as measured by -- in either of the two dose levels tested. We're reviewing the data for presentation of detailed results of the study at the clinica”